Skip to main content

Advertisement

SpringerLink
Log in

Individualized Fludarabine-Based Regimen in Elderly Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The aim of this study was to investigate the efficacy and safety of a fludarabine-based individualized regimen in elderly patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Methods

Sixteen patients were treated with the individual regimen of fludarabine combined with rituximab. Adverse reactions and efficacy of treatment were observed.

Results

Sixteen patients received a total of 69 courses of immunochemotherapy, with an average administration of 275 mg fludarabine per person. The overall response rate was 81.3% (13/16), in which seven cases (43.8%) achieved complete remission, six cases (37.5%) achieved partial remission, two cases (12.5%) had stable disease, and one case (6.3%) developed disease progression. The most frequent side effect was myelosuppression. Two patients experienced grade 3–4 cytopenia, one case developed a grade 3 infection, and no treatment-related death was observed.

Conclusion

The individual regimen of fludarabine combined with rituximab demonstrated marked clinical efficacy and acceptable toxicity in elderly patients with CLL/SLL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lin TS. What is the optimal initial treatment for chronic lymphocytic leukemia? Oncology (Williston Park). 2007;21:1641–1649.

    Google Scholar 

  2. Guo B, Zhu H-L, Li S-X, et al. Individualized liposomal doxorubicin-based treatment in elderly patients with non-Hodgkin lymphoma. Oncologie. 2011;34:184–188.

    Article  CAS  Google Scholar 

  3. Ferrajoli A, O’Brien S, Wierda W, et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma. 2005;46:S86.

    Google Scholar 

  4. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood. 2008;111:5446–5456.

    Article  PubMed  CAS  Google Scholar 

  5. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–1757.

    Article  PubMed  CAS  Google Scholar 

  6. Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100:3115–3120.

    Article  PubMed  CAS  Google Scholar 

  7. Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975–980.

    Article  PubMed  CAS  Google Scholar 

  8. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–1765.

    Article  PubMed  CAS  Google Scholar 

  9. Foon KA, Boyiadzis M, Land SR, Pietragallo L, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high-dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:498–503.

    Article  PubMed  CAS  Google Scholar 

  10. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885–891.

    Article  PubMed  CAS  Google Scholar 

  11. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29:1349–1355.

    Article  PubMed  CAS  Google Scholar 

  12. Zhu H-L, Fan H, Yao S. A case study of fludarabine treatment of prolymphocytic leukemia in elderly. Journal of Internal Medicine. 2000;39:351–353.

    Article  Google Scholar 

  13. Liu Y, Zhu H-L, Lu X-C. The treatment of fludarabine combined with CD antibody and amifostine of elderly chronic lymphocytic leukemia. Chinese Laboratory Journal of Hematology. 2007;15:989–992.

    CAS  Google Scholar 

  14. Keating M, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–4088.

    Article  PubMed  CAS  Google Scholar 

  15. Del Poeta G, Del Principe MI, Irno Consalvo MA, et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia. Cancer. 2005;104:2743–2752.

    Article  PubMed  Google Scholar 

  16. Byrd JC, Rai K, Peterson BL, et a1. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Hospital of People’s Liberation Army, 28 # Fu Xing Road, 100853, Beijing, China

    Bo Guo, Hong-Li Zhu, Hui Fan, Su-Xia Li, Xue-Chun Lu, Jie Lin, Hai-Hong Ran, Bing Zhai & Yang Yang

Authors
  1. Bo Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong-Li Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Su-Xia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xue-Chun Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jie Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hai-Hong Ran
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bing Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong-Li Zhu.

Additional information

To view enhanced content go to www.advancesintherapy.com

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guo, B., Zhu, HL., Fan, H. et al. Individualized Fludarabine-Based Regimen in Elderly Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Adv Therapy 29, 178–186 (2012). https://doi.org/10.1007/s12325-011-0097-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-011-0097-y

Keywords

Search

Navigation